poisar

Stocks · News reference

Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

Aug 14, 2026, 7:52 PMBenzinga Newsdesk

Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LGND
Source
benzinga
Observed
Aug 14, 2026, 7:52 PM
Checked
Aug 14, 2026, 7:52 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 11:00 AMNa

    Ligand to Participate in September Investor Conferences

    Ligand Pharmaceuticals announced that its senior management team will participate in three upcoming investor conferences in September 2026: Wells Fargo Healthcare Conference (September 8), Citi 2026 Biopharma Back to School Conference (September 10), and H.C. Wainwright 28th Annual Global Investment Conference (September 14). The company will host fireside chats and one-on-one meetings with investors at these events.

    Read original at globenewswire-inc
    LGND